Quick facts
- Class
- Melanocortin receptor agonist
- Studied for
- Melanogenesis (tanning), libido
- Key concern
- Unregulated; reported adverse effects
- Approval
- Not FDA-approved
- Class
- Synthetic melanocortin receptor agonist (alpha-MSH analog)
- Approval status
- Not approved by the FDA, EMA, or other major regulators
- Common use
- Sold online for tanning, libido, and appetite effects
- Route
- Typically subcutaneous injection
Key takeaways
- Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone that activates melanocortin receptors to stimulate skin pigmentation.
- It is not approved by any major regulatory agency for any use and is sold as an unregulated research chemical, typically via injection.
- Reported effects include skin darkening, appetite suppression, and increased libido (it is the parent compound of the drug bremelanotide).
- Safety concerns include nausea and flushing, and reports of new or changing moles, prompting recommendations for dermatologic monitoring of nevi and melanoma risk.
- Product purity, sterility, and dosing are unverified because it is sold outside regulated pharmaceutical supply chains.
Overview
Melanotan-2 (often abbreviated MT-2) is a synthetic peptide that acts on melanocortin receptors. It was originally explored in research as a way to stimulate skin pigmentation, leading to its popular promotion as a tanning agent, and it is also known for effects on sexual arousal.
It is closely related, by mechanism, to the approved drug bremelanotide (PT-141), since both act on the melanocortin system. However, melanotan-2 itself is not an approved medication anywhere as a tanning product. It is sold through unregulated channels, frequently online, as an injectable peptide.
Health authorities in several countries have issued warnings about melanotan-2, citing both the lack of approval and specific safety concerns. It should be understood as an unapproved, unregulated substance rather than a legitimate cosmetic or medical product, and its widespread informal use does not reflect any endorsement of its safety or quality.
How it works
Melanotan-2 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) and activates several melanocortin receptors. Its activity at the MC1 receptor stimulates melanocytes in the skin to produce more melanin, which is the basis for its tanning effect and can occur with less ultraviolet exposure than natural tanning.
Through its action at other receptors in the melanocortin family, particularly MC4 in the central nervous system, it also influences sexual arousal and appetite. This is why users frequently report effects on libido as well as pigmentation, and it is the same receptor pathway exploited by the approved drug bremelanotide.
Because melanotan-2 acts broadly across multiple melanocortin receptors rather than selectively, it can produce a wide range of effects at once. This lack of selectivity, combined with unregulated dosing, is part of why its effects and side effects can be unpredictable, and why activating these receptors raises specific concerns about skin and pigmented lesions.
Research & evidence
Melanotan-2 originated from legitimate scientific interest in the melanocortin system, but it was not developed into an approved product for tanning. The most rigorous clinical development in this area went to related, more selective compounds, leaving melanotan-2 itself without a completed approval pathway.
As a result, the evidence supporting its widespread informal use is limited and does not establish safety. While its pigmentation and arousal effects are biologically plausible and reported by users, there are no large, well-controlled trials demonstrating that it can be used safely as a cosmetic tanning agent over time.
A particular research and clinical concern is its effect on moles and pigmented lesions. Reports have described changes in the number, size, and appearance of nevi in users, which is significant because such changes can complicate the monitoring of skin for melanoma. This makes the absence of proper safety data especially serious for a product marketed for routine cosmetic use.
Safety & legal status
Melanotan-2 carries notable safety concerns. Commonly reported effects include nausea, flushing, decreased appetite, and darkening not only of the skin but of existing moles and freckles. More importantly, the changes it can cause in pigmented lesions raise concern about skin cancer surveillance, since new or changing moles are a key warning sign clinicians rely on to detect melanoma.
Because it is sold through unregulated channels, products are not manufactured to pharmaceutical standards, and purity, sterility, and accurate concentration cannot be assured. Injecting an unregulated peptide adds further risk of contamination and infection.
Legally, melanotan-2 is not approved as a medicine or cosmetic in major markets, and several national health agencies have explicitly warned against its use. Anyone who has used it and notices changes in their skin or moles should seek evaluation from a healthcare professional. The combination of unproven safety, unregulated sourcing, and melanoma-surveillance concerns makes this a substance to approach with serious caution.
Frequently asked questions
Is Melanotan II legal or approved?
Melanotan II is not approved for human use by the FDA, EMA, or other major regulators. It is sold as an unregulated research chemical, and several countries have issued warnings against its sale and use.
How is Melanotan II different from afamelanotide?
Both are melanocortin-pathway peptides, but afamelanotide (Melanotan I) is an approved prescription drug for a specific rare disorder, while Melanotan II is an unapproved, unregulated compound sold online. They are distinct molecules with different regulatory and safety profiles.
What are the main safety concerns with Melanotan II?
Commonly reported effects include nausea, facial flushing, and darkening of moles. Because it can alter the appearance of nevi, clinicians have raised concerns about melanoma surveillance, and the unregulated supply means purity and sterility are not guaranteed.
Is Melanotan II related to any approved medication?
Yes. Bremelanotide, an approved treatment for certain cases of low sexual desire, is a melanocortin agonist derived from research on Melanotan II. The two are not interchangeable, and Melanotan II itself remains unapproved.
Why do people use Melanotan II despite the risks?
Users typically seek faster skin tanning with less sun exposure, and some report appetite or libido effects. These uses are not supported by regulatory approval, and the safety trade-offs are significant.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014. Peer-reviewed study
- Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009. Peer-reviewed study
- Peters B, Hadimeri H, Wahlberg R, et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020. Peer-reviewed study
- Wekwejt P, Wojda U, Kiryk A. Melanotan-II reverses memory impairment induced by a short-term HF diet. Biomed Pharmacother. 2023. Peer-reviewed study
- Gilhooley E, Daly S, McKenna D. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology. 2021. Peer-reviewed study
- Tomassi S, Dimmito MP, Cai M, et al. CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. J Med Chem. 2022. Peer-reviewed study